Estimated proportion of cancer deaths not addressed by current cancer screening efforts in the United States.

IF 2.2 4区 医学 Q3 ONCOLOGY
Cancer Biomarkers Pub Date : 2025-01-01 Epub Date: 2025-03-20 DOI:10.1177/18758592241308754
Joshua J Ofman, William Dahut, Ahmedin Jemal, Ellen T Chang, Christina A Clarke, Earl Hubbell, Anuraag R Kansal, Allison W Kurian, Graham A Colditz, Alpa V Patel
{"title":"Estimated proportion of cancer deaths not addressed by current cancer screening efforts in the United States.","authors":"Joshua J Ofman, William Dahut, Ahmedin Jemal, Ellen T Chang, Christina A Clarke, Earl Hubbell, Anuraag R Kansal, Allison W Kurian, Graham A Colditz, Alpa V Patel","doi":"10.1177/18758592241308754","DOIUrl":null,"url":null,"abstract":"<p><p>BackgroundIt is unclear what proportion of the population cancer burden is covered by current implementation of USPSTF A/B screening recommendations.ObjectiveWe estimated the proportion of all US cancer deaths caused by cancer types not covered by screening recommendations or cancer types covered but unaddressed by current implementation.MethodsWe used 2018-2019 National Center for Health Statistics mortality data, Surveillance, Epidemiology, and End Results registries incidence-based mortality data, and published estimates of screening eligibility and receipt.ResultsOf approximately 600,000 annual cancer deaths in the US, 31.4% were from screenable cancer types, including colorectal, female breast, cervical, and smoking-associated lung cancers. Further accounting for the low receipt of lung cancer screening reduced the proportion to 17.4%; accounting for receipt of other screening reduced it to 12.8%. Thus, we estimated that current implementation of recommended screening may not address as much as 87.2% of cancer deaths<i>-</i>including 30.4% from individually uncommon cancer types unlikely ever to be covered by dedicated screening.ConclusionsThe large proportion of cancer deaths unaddressed by current screening represents a major opportunity for improved implementation of current approaches, as well as new multi-cancer screening technologies.</p>","PeriodicalId":56320,"journal":{"name":"Cancer Biomarkers","volume":"42 1","pages":"18758592241308754"},"PeriodicalIF":2.2000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/18758592241308754","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

BackgroundIt is unclear what proportion of the population cancer burden is covered by current implementation of USPSTF A/B screening recommendations.ObjectiveWe estimated the proportion of all US cancer deaths caused by cancer types not covered by screening recommendations or cancer types covered but unaddressed by current implementation.MethodsWe used 2018-2019 National Center for Health Statistics mortality data, Surveillance, Epidemiology, and End Results registries incidence-based mortality data, and published estimates of screening eligibility and receipt.ResultsOf approximately 600,000 annual cancer deaths in the US, 31.4% were from screenable cancer types, including colorectal, female breast, cervical, and smoking-associated lung cancers. Further accounting for the low receipt of lung cancer screening reduced the proportion to 17.4%; accounting for receipt of other screening reduced it to 12.8%. Thus, we estimated that current implementation of recommended screening may not address as much as 87.2% of cancer deaths-including 30.4% from individually uncommon cancer types unlikely ever to be covered by dedicated screening.ConclusionsThe large proportion of cancer deaths unaddressed by current screening represents a major opportunity for improved implementation of current approaches, as well as new multi-cancer screening technologies.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Biomarkers
Cancer Biomarkers ONCOLOGY-
CiteScore
5.20
自引率
3.20%
发文量
195
审稿时长
3 months
期刊介绍: Concentrating on molecular biomarkers in cancer research, Cancer Biomarkers publishes original research findings (and reviews solicited by the editor) on the subject of the identification of markers associated with the disease processes whether or not they are an integral part of the pathological lesion. The disease markers may include, but are not limited to, genomic, epigenomic, proteomics, cellular and morphologic, and genetic factors predisposing to the disease or indicating the occurrence of the disease. Manuscripts on these factors or biomarkers, either in altered forms, abnormal concentrations or with abnormal tissue distribution leading to disease causation will be accepted.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信